STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 134293

TO: Kevin Weddington **Location: rem/3c70** **Art Unit: 1614** **October 5, 2004** **Case Serial Number: 10/657570**	**From: P. Sheppard** **Location: Remsen Building** **Phone: (571) 272-2529** **sheppard@uspto.gov**

Search Notes

```
=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 10:44:43 ON 05 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 5 Oct 2004  VOL 141 ISS 15
FILE LAST UPDATED: 4 Oct 2004  (20041004/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=>
=>

=> d stat que
L3                STR
```





```
VAR G1=26-3 27-7/29-3 30-7/32-3 33-7/34-3 35-7/35-3 34-7/33-3 32-7/30-3 2
9-7/27-3 26-7
REP G2=(0-2) C
VAR G3=O/S/N
NODE ATTRIBUTES:
NSPEC    IS RC     AT  15
NSPEC    IS RC     AT  16
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  36

STEREO ATTRIBUTES: NONE
L5            25 SEA FILE=REGISTRY SSS FUL L3
L6             4 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L5
```

=>
=>

=> d ibib abs hitstr l6 1-4

L6 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1998:785655 HCAPLUS
DOCUMENT NUMBER: 130:25348
TITLE: Preparation of meta-substituted phenylenesulfonamide derivatives as avβ3 integrin antagonists
INVENTOR(S): Chandrakumar, Nizal; Clare, Michael; Doubleday, Wendell; Gasiecki, Alan F.; Russell, Mark A.
PATENT ASSIGNEE(S): G.D. Searle and Co., USA
SOURCE: U.S., 24 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 5843906	A	19981201	US 1997-824626		19970327
US 6677308	B1	20040113	US 1998-141547		19980828
PRIORITY APPLN. INFO.:			US 1996-14415P	P	19960329
			US 1997-824626	A3	19970327

OTHER SOURCE(S): MARPAT 130:25348
GI



I



II

AB The present invention relates title compds. I [B = CONR50, SO2NR50; A = NR5C(:Y1)NR7R8, NR5Y2:NR7; Y1 = NR2, O, S; Y2 = H, (un)substituted alkyl, cycloalkyl, bicycloalkyl, aryl, monocyclic heterocycle; R2 = H, OH, CN, NO2, (un)substituted alkyl, aryl, amino, alkenyl, alkynyl; R2R7 from 4-12-membered optionally fused ring; R7, R8 = independently H, (un)substituted alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, bicycloalkyl, aryl, acyl, benzoyl; Y2R7, R7R8 may from 4-12-membered mono- or bicyclic ring; R5 = H, alkyl, alkenyl, alkynyl, PhCH2, PhCH2CH2; Z1, Z2, Z4, Z5 = independently H; alkyl, OH, alkoxy, aryloxy, aralkoxy, halo, haloalkyl haloalkoxy, NO2, amino, aminoalkyl, alkylamino, dialkylamino,

CN, alkylthio, alkylsulfonyl, carboxyl derivs., acetamide, (fused) aryl, cycloalkyl, thio, (fused) monocyclic heterocycle, group A; R50 = H, alkyl; R1 = H, (un)substituted alkyl, alkenyl, alkynyl, aryl; n = 0-2; R = XR3; X = O, S, NR4; R3, R4 = independently H, (un)substituted alkyl, alkenyl, alkynyl, haloalkyl, aryl, arylalkyl, sugar residue, steroid residue; Y3, Z3 = independently H, alkyl, aryl, cycloalkyl, aralkyl] or a pharmaceutically acceptable salt thereof, pharmaceutical compns. comprising I, and methods of selectively inhibiting or antagonizing the αvβ3 integrin. Thus, amidation of 3-H2NC6H4SO2NHCHPhCH2CO2Et (preparation given) with protected 3-guanidinobenzoic acid, followed by deprotection gave desired title compound II as its trifluoroacetate salt. II inhibited binding to human vitronectin receptor (αvβ3) and human fibrinogen receptor (αIIbβ3) with IC50 = 1.66 nM and 11.3 nM, resp.

IT **197719-47-4P 197719-50-9P 197719-52-1P**
197719-55-4P 197719-58-7P 197719-63-4P
197719-65-6P 216386-46-8P 216386-47-9P
216386-48-0P 216386-49-1P 216386-50-4P
216386-52-6P 216386-53-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted phenylenesulfonamide derivs. as vitronectin and fibrinogen receptor antagonists)

RN 197719-47-4 HCAPLUS
CN Benzenepropanoic acid, β-[[[3-[[3-[(aminoiminomethyl)amino]benzoyl]amino]phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 197719-50-9 HCAPLUS
CN 4-Pentynoic acid, 3-[[[3-[[3-[(aminoiminomethyl)amino]benzoyl]amino]phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 197719-52-1 HCAPLUS
CN 4-Pentenoic acid, 3-[[[3-[[3-[(aminoiminomethyl)amino]benzoyl]amino]phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 197719-55-4 HCAPLUS
CN Benzenepropanoic acid, β-[[[3-[[3-[(aminoiminomethyl)amino]benzoyl]amino]phenyl]sulfonyl]amino]-3,5-dichloro- (9CI) (CA INDEX NAME)





RN 197719-58-7 HCAPLUS
CN 3-Pyridinepropanoic acid, β-[[[3-[[3-[(aminoiminomethyl)amino]benzoyl]amino]phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 197719-63-4 HCAPLUS
CN 4-Pentynoic acid, 3-[[[3-[[3-[(4,5-dihydro-1H-imidazol-2-yl)amino]benzoyl]amino]phenyl]sulfonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 197719-65-6 HCAPLUS
CN Benzenepropanoic acid, β-[[[3-[[[3-[(aminoiminomethyl)amino]phenyl]sulfonyl]amino]phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 216386-46-8 HCAPLUS
CN Benzenepropanoic acid, β-[[[3-[[3-[(aminoiminomethyl)amino]benzoyl]amino]phenyl]sulfonyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 197719-47-4
CMF C23 H23 N5 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 216386-47-9 HCAPLUS
CN 4-Pentynoic acid, 3-[[[3-[[3-[(aminoiminomethyl)amino]benzoyl]amino]phenyl]sulfonyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 197719-50-9
CMF C19 H19 N5 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 216386-48-0 HCAPLUS
CN 4-Pentenoic acid, 3-[[[3-[[3-[(aminoiminomethyl)amino]benzoyl]amino]phenyl]sulfonyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 197719-52-1
CMF C19 H21 N5 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 216386-49-1 HCAPLUS
CN Benzenepropanoic acid, β-[[[3-[[3-[(aminoiminomethyl)amino]benzoyl]amino]phenyl]sulfonyl]amino]-3,5-dichloro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 197719-55-4
CMF C23 H21 Cl2 N5 O5 S





CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 216386-50-4 HCAPLUS
CN 3-Pyridinepropanoic acid, β-[[[3-[[3-[(aminoiminomethyl)amino]benzoyl]amino]phenyl]sulfonyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 197719-58-7
CMF C22 H22 N6 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 216386-52-6 HCAPLUS
CN 4-Pentynoic acid, 3-[[[3-[[3-[(4,5-dihydro-1H-imidazol-2-yl)amino]benzoyl]amino]phenyl]sulfonyl]amino]-, (3S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 197719-63-4
CMF C21 H21 N5 O5 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 216386-53-7 HCAPLUS
CN Benzenepropanoic acid, β-[[[3-[[[3-[(aminoiminomethyl)amino]phenyl]sulfonyl]amino]phenyl]sulfonyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 197719-65-6
CMF C22 H23 N5 O6 S2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT **197719-73-6P 197719-75-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted phenylenesulfonamide derivs. as vitronectin and fibrinogen receptor antagonists)

RN 197719-73-6 HCAPLUS
CN Benzenepropanoic acid, β-[[[3-[[3-[[bis[[(1,1-dimethylethoxy)carbonyl]amino]methylene]amino]benzoyl]amino]phenyl]sulfonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 197719-75-8 HCAPLUS
CN Benzenepropanoic acid, β-[[[3-[[[3-[[bis[[(1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]sulfonyl]amino]phenyl]sulfonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1998:56108 HCAPLUS
DOCUMENT NUMBER: 128:162545
TITLE: Antiangiogenic and antiproliferative activity of suramin analogs
AUTHOR(S): Gagliardi, Antonio R. T.; Kassack, Matthias; Kreimeyer, Annett; Muller Guido; Nickel, Peter; Collins, Delwood C.
CORPORATE SOURCE: VA Medical Center, Department Obstetrics/Gynecology, College Medicine, University Kentucky, Lexington, KY, 40536, USA
SOURCE: Cancer Chemotherapy and Pharmacology (1998), 41(2), 117-124
CODEN: CCPHDZ; ISSN: 0344-5704
PUBLISHER: Springer-Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Polyanionic suramin analogs were tested for their ability to inhibit angiogenesis. The ID50 was determined in the chick egg chorioallantoic membrane assay. Of 70 analogs 11 had antiangiogenic activities similar to suramin and 7 were more potent than suramin, the latter being from the naphthalenetrisulfonic acid group and containing large urea groups. The benzene sulfonic and disulfonic acid analogs were less active than the naphthalenetrisulfonic acid analogs. Replacement of the naphthalenetrisulfonic acid groups by aliphatic carboxylic acids or benzoic acid gave analogs with very little antiangiogenic activity. The antiproliferative activity of selected analogs on basic fibroblast growth factor-stimulated growth of immortalized microvascular endothelial cells was determined The analogs that inhibited angiogenesis to a greater extent than suramin showed a greater antiproliferative effect. The authors suggest that some of the polyanionic analogs may be potent therapeutic agents for cancer and angiogenesis-dependent diseases.

IT **202983-49-1**, NF 186
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(antiangiogenic and antiproliferative activity of suramin analogs)

RN 202983-49-1 HCAPLUS
CN L-Aspartic acid, N,N'-[carbonylbis(imino-3,1-phenylenecarbonylimino-3,1-phenylenesulfonyl)]bis-, tetrasodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





L6 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1997:679051 HCAPLUS
DOCUMENT NUMBER: 127:318777
TITLE: Preparation of guanidinophenylsulfonylaminophenylsulfonylaminophenylpropanoates as αvβ3 integrin inhibitors.
INVENTOR(S): Chandrakumar, Nizal; Clare, Michael; Doubleday, Wendell; Gasiecki, Alan F.; Russell, Mark A.
PATENT ASSIGNEE(S): G.D. Searle and Co., USA; Chandrakumar, Nizal; Clare, Michael; Doubleday, Wendell; Gasiecki, Alan F.; Russell, Mark A.
SOURCE: PCT Int. Appl., 97 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9736861	A1	19971009	WO 1997-US3986	19970320
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2250586	AA	19971009	CA 1997-2250586	19970320
AU 9724208	A1	19971022	AU 1997-24208	19970320
EP 889876	A1	19990113	EP 1997-919877	19970320
EP 889876	B1	20010725		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2000507952	T2	20000627	JP 1997-535278	19970320
AT 203515	E	20010815	AT 1997-919877	19970320
ES 2160949	T3	20011116	ES 1997-919877	19970320
GR 3036887	T3	20020131	GR 2001-401757	20011016

PRIORITY APPLN. INFO.: US 1996-14415P P 19960329
WO 1997-US3986 W 19970320

OTHER SOURCE(S): MARPAT 127:318777
GI



I

AB Title compds. [I; B = CONR50, SO2NR50; A = NR5C(Y1)NR7R8, NR5CY2(NR7); X = O, S, NR4; Y1 = NR2, O, S; R = XR3; Y2 = H, (substituted) alkyl, cycloalkyl bicycloalkyl, aryl, heterocyclyl,etc.; R1 = H, alkyl, alkenyl, alkynyl, (substituted) aryl; R2 = H, alkyl, aryl, OH, alkoxy, cyano, NO2, amino, alkenyl, alkynyl, etc.; Y2R7 = (substituted) heterocyclyl; R3, R4 = H, alkyl, alkenyl, alkynyl, haloalkyl, aryl, aralkyl, sugar residue, steroid residue; R5 = H, alkyl, alkenyl, alkynyl, PhCH2, PhCH2CH2; R7, R8 = H, (substituted) alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, bicycloalkyl, aryl, acyl, etc.; R2R7, R7R8 = (substituted) heterocyclyl; R50 = H, alkyl; Z1, Z2, Z3, Z4 = H, alkyl, OH, alkoxy, aryloxy, aralkoxy, halo, haloalkyl, haloalkoxy, NO2, amino, aminoalkyl, cyano, alkylthio, alkylsulfonyl, carboxyl derivs., (fused) aryl, cycloalkyl, (fused) heterocyclyl, etc.; Y3, Z3 = H, alkyl, aryl, cycloalkyl, aralkyl; m = 0-2], were prepared Thus, β-[[[3-[[[3-[(aminoiminomethyl)amino]phenyl] carbonyl]amino]phenyl]sulfonyl]amino]benzenepropanoic acid trifluoroacetate (preparation given) inhibited αvβ3 integrin with IC50 = 1.66 nM.

IT **197719-47-4P 197719-48-5P 197719-50-9P**
197719-51-0P 197719-52-1P 197719-53-2P
197719-55-4P 197719-56-5P 197719-58-7P
197719-59-8P 197719-63-4P 197719-64-5P
197719-66-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of guanidinophenylsulfonylaminophenylsulfonylaminophenylpropanoates as αvβ3 integrin inhibitors)

RN 197719-47-4 HCAPLUS
CN Benzenepropanoic acid, β-[[[3-[[3-[(aminoiminomethyl)amino]benzoyl]amino]phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 197719-48-5 HCAPLUS
CN Benzenepropanoic acid, β-[[[3-[[3-[(aminoiminomethyl)amino]benzoyl]amino]phenyl]sulfonyl]amino]-, trifluoroacetate (2:5) (9CI) (CA INDEX NAME)

CM 1

CRN 197719-47-4
CMF C23 H23 N5 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 197719-50-9 HCAPLUS
CN 4-Pentynoic acid, 3-[[[3-[[3-[(aminoiminomethyl)amino]benzoyl]amino]phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 197719-51-0 HCAPLUS
CN 4-Pentynoic acid, 3-[[[3-[[3-[(aminoiminomethyl)amino]benzoyl]amino]phenyl]sulfonyl]amino]-, trifluoroacetate (10:13) (9CI) (CA INDEX NAME)

CM 1

CRN 197719-50-9
CMF C19 H19 N5 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 197719-52-1 HCAPLUS
CN 4-Pentenoic acid, 3-[[[3-[[3-[(aminoiminomethyl)amino]benzoyl]amino]phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 197719-53-2 HCAPLUS
CN 4-Pentenoic acid, 3-[[[3-[[3-[(aminoiminomethyl)amino]benzoyl]amino]phenyl]sulfonyl]amino]-, trifluoroacetate (10:13) (9CI) (CA INDEX NAME)

CM 1

CRN 197719-52-1
CMF C19 H21 N5 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 197719-55-4 HCAPLUS
CN Benzenepropanoic acid, β-[[[3-[[3-[(aminoiminomethyl)amino]benzoyl]amino]phenyl]sulfonyl]amino]-3,5-dichloro- (9CI) (CA INDEX NAME)





RN 197719-56-5 HCAPLUS

CN Benzenepropanoic acid, β-[[[3-[[3-[(aminoiminomethyl)amino]benzoyl]amino]phenyl]sulfonyl]amino]-3,5-dichloro-, trifluoroacetate (5:6) (9CI) (CA INDEX NAME)

CM 1

CRN 197719-55-4
CMF C23 H21 Cl2 N5 O5 S





CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 197719-58-7 HCAPLUS
CN 3-Pyridinepropanoic acid, β-[[[3-[[3-[(aminoiminomethyl)amino]benzoyl]amino]phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 197719-59-8 HCAPLUS
CN 3-Pyridinepropanoic acid, β-[[[3-[[3-[(aminoiminomethyl)amino]benzoyl]amino]phenyl]sulfonyl]amino]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 197719-58-7
CMF C22 H22 N6 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 197719-63-4 HCAPLUS
CN 4-Pentynoic acid, 3-[[[3-[[3-[(4,5-dihydro-1H-imidazol-2-yl)amino]benzoyl]amino]phenyl]sulfonyl]amino]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 197719-64-5 HCAPLUS
CN 4-Pentynoic acid, 3-[[[3-[[3-[(4,5-dihydro-1H-imidazol-2-yl)amino]benzoyl]amino]phenyl]sulfonyl]amino]-, (S)-, trifluoroacetate (10:13) (9CI) (CA INDEX NAME)

CM 1

CRN 197719-63-4
CMF C21 H21 N5 O5 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 197719-66-7 HCAPLUS
CN Benzenepropanoic acid, β-[[[3-[[[3-[(aminoiminomethyl)amino]phenyl]sulfonyl]amino]phenyl]sulfonyl]amino]-, trifluoroacetate (2:3) (9CI) (CA INDEX NAME)

CM 1

CRN 197719-65-6
CMF C22 H23 N5 O6 S2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT **197719-75-8**
RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of guanidinophenylsulfonylaminophenylsulfonylaminophenylpropano ates as αvβ3 integrin inhibitors)

RN 197719-75-8 HCAPLUS

CN Benzenepropanoic acid, β-[[[3-[[[3-[[bis[[(1,1-dimethylethoxy)carbonyl]amino]methylene]amino]phenyl]sulfonyl]amino]phenyl]sulfonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



IT **197719-73-6P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of guanidinophenylsulfonylaminophenylsulfonylaminophenylpropano ates as αvβ3 integrin inhibitors)

RN 197719-73-6 HCAPLUS

CN Benzenepropanoic acid, β-[[[3-[[3-[[bis[[(1,1-dimethylethoxy)carbonyl]amino]methylene]amino]benzoyl]amino]phenyl]sulfonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



L6 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1991:229348 HCAPLUS

DOCUMENT NUMBER: 114:229348

TITLE: Carboxylic acid analogs of suramin, potential filaricides

AUTHOR(S): Nickel, Peter; Schott, Erich; Gurgel, Christiane; Duwel, Dieter; Raether, Wolfgang

CORPORATE SOURCE: Pharm. Inst., Univ. Bonn, Bonn, D-5300/1, Germany

SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1991), 30B(2), 182-7
CODEN: IJSBDB; ISSN: 0376-4699

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 114:229348

GI



I

AB A series of suramin analogs has been synthesized in which the naphthylaminetrisulfonic acid residues of the suramin mol. have been replaced by the aliphatic amino acids; aspartic acids, glutamic acid, or iminodiacetic acid. Among the aspartic acid derivs., urea derivative I shows moderate, selective antifilarial activity.

IT **133808-69-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and antifilarial activity of)

RN 133808-69-2 HCAPLUS

CN L-Aspartic acid, N,N'-[carbonylbis(imino-3,1-phenylenecarbonylimino-3,1-phenylenesulfonyl)]bis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



=> => fil caold
FILE 'CAOLD' ENTERED AT 10:45:09 ON 05 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate

substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=>
=>

=> s l5
L7 0 L5

=>
=>

=> □

=> fil beil
FILE 'BEILSTEIN' ENTERED AT 10:47:07 ON 05 OCT 2004
COPYRIGHT (c) 2004 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften licensed to Beilstein GmbH and MDL Information Systems GmbH

FILE RELOADED ON OCTOBER 20, 2002
FILE LAST UPDATED ON JUNE 15, 2004

FILE COVERS 1771 TO 2003.
*** FILE CONTAINS 8,997,153 SUBSTANCES ***

>>>PLEASE NOTE: Reaction Data and substance data are stored in separate documents and can not be searched together in one query. Reaction data for BEILSTEIN compounds may be displayed immediately with the display codes PRE (preparations) and REA (reactions). A substance answer set retrieved after the search for a chemical name, a compounds with available reaction information by combining with PRE/FA, REA/FA or more generally with RX/FA. The BEILSTEIN Registry Number (BRN) is the link between a BEILSTEIN compound and belonging reactions. For mo detailed reaction searches BRNs can be searched as reaction partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE <<<

****
* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST. *
* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE *
* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE *
* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS. *
* FOR PRICE INFORMATION SEE HELP COST *
****

NEW
*** PATENT NUMBERS (PN) AND BABS ACCESSION NUMBERS (BABSAN) CAN NOW BE SEARCHED, SELECTED AND TRANSFERRED.**
*** NEW DISPLAY FORMATS ALLREF, ALLP AND BABSAN SHOW ALL REFERENCES, ALL PATENT REFERENCES, OR ALL BABS ACCESSION NUMBERS FOR A COMPOUND AT A GLANCE.**

=>
=>